Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders

被引:13
|
作者
Katagiri, Takenobu [1 ,2 ]
Tsukamoto, Sho [1 ,2 ]
Kuratani, Mai [1 ]
机构
[1] Saitama Med Univ, Res Ctr Genom Med, Div Biomed Sci, Hidaka, Saitama 3501241, Japan
[2] Saitama Med Univ, Project Clin & Basic Res FOP, Hidaka, Saitama 3501241, Japan
关键词
activin receptor-like kinase 2 (ALK2); activin a receptor; type I (ACVR1); genetic disorder; animal model; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; BONE MORPHOGENETIC PROTEINS; HETEROTOPIC OSSIFICATION; MUTATION; ALK2; MOUSE; GENE; INVOLVEMENT; MECHANISMS; INHIBITION;
D O I
10.3390/biomedicines9070736
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activin receptor-like kinase 2 (ALK2), also known as Activin A receptor type 1 (ACVR1), is a transmembrane kinase receptor for members of the transforming growth factor-beta family. Wild-type ALK2/ACVR1 transduces osteogenic signaling in response to ligand binding. Fifteen years ago, a gain-of-function mutation in the ALK2/ACVR1 gene was detected in patients with the genetic disorder fibro-dysplasia ossificans progressiva, which is characterized by heterotopic ossification in soft tissues. Additional disorders, such as diffuse intrinsic pontin glioma, diffuse idiopathic skeletal hyperostosis, primary focal hyperhidrosis, and congenital heart defects, have also been found to be associated with ALK2/ACVR1. These findings further expand in vitro and in vivo model system research and promote our understanding of the molecular mechanisms of the pathogenesis and development of novel therapeutics and diagnosis for disorders associated with ALK2/ACVR1. Through aggressive efforts, some of the disorders associated with ALK2/ACVR1 will be overcome in the near future.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] A case of fibro-dysplasia ossificans progressiva with a novel mutation (G356D) of the activin receptor type 1 gene (ACVR1(ALK2))
    Furuya, H.
    Ikezoe, K.
    Fujii, N.
    Kira, J. I.
    Arahata, H.
    Fukumaki, Y.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 788 - 788
  • [2] The Type I BMP Receptor ACVR1/ALK2 is Required for Chondrogenesis During Development
    Rigueur, Diana
    Brugger, Sean
    Anbarchian, Teni
    Kim, Jong Kil
    Lee, YooJin
    Lyons, Karen M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (04) : 733 - 741
  • [3] Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor
    Renlund, Nina
    O'Neill, Francis H.
    Zhang, LiHua
    Sidis, Yisrael
    Teixeira, Jose
    JOURNAL OF ENDOCRINOLOGY, 2007, 195 (01) : 95 - 103
  • [4] Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia
    Tyagi, Anudishi
    Ly, Stanley
    Bin Yuan
    El-Dana, Fouad
    Anand, Vivek
    Jaggupilli, Appalaraju
    Borthakur, Gautam
    Foulks, Jason M.
    Warner, Steven L.
    Battula, Venkata Lokesh
    BLOOD, 2022, 140 : 3052 - 3053
  • [5] Involvement of activin a receptor type 1 (ACVR1) in the pathogenesis of primary focal hyperhidrosis
    Lin, Jian-Bo
    Chen, Jian-Feng
    Lai, Fan-Cai
    Li, Xu
    Xie, Jin-Bao
    Tu, Yuan-Rong
    Kang, Ming-Qiang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 528 (02) : 299 - 304
  • [6] Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function
    de Vinuesa, Amaya Garcia
    Bocci, Matteo
    Pietras, Kristian
    ten Dijke, Peter
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 1142 - 1149
  • [7] Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2
    Johnson, DW
    Berg, JN
    Baldwin, MA
    Gallione, CJ
    Marondel, I
    Yoon, SJ
    Stenzel, TT
    Speer, M
    PericakVance, MA
    Diamond, A
    Guttmacher, AE
    Jackson, CE
    Attisano, L
    Kucherlapati, R
    Porteous, MEM
    Marchuk, DA
    NATURE GENETICS, 1996, 13 (02) : 189 - 195
  • [8] Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy
    Hawinkels, Lukas J. A. C.
    de Vinuesa, Amaya Garcia
    ten Dijke, Peter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (11) : 1371 - 1383
  • [9] Molecular mechanisms of the activation of BMP signaling by ligands through ALK2/ACVR1 receptor and the inhibition of signaling by an anti-ALK2/ACVR1 antibody
    Katagiri, Takenobu
    Tsukamoto, Sho
    Kuratani, Mai
    Tsuji, Shinnosuke
    Takaishi, Kiyosumi
    Kunikata, Tomonori
    Nakamura, Kensuke
    Kawaguchi, Yoshiro
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 117 - 117
  • [10] CLONING AND CHARACTERIZATION OF THE MURINE ACTIVIN RECEPTOR-LIKE KINASE-1 (ALK-1) HOMOLOG
    WU, XY
    ROBINSON, CE
    FONG, HW
    CRABTREE, JS
    RODRIGUEZ, BR
    ROE, BA
    GIMBLE, JM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 216 (01) : 78 - 83